Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03948035
Title Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Wuerzburg University Hospital

multiple myeloma


Carfilzomib + Dexamethasone + Lenalidomide

Carfilzomib + Dexamethasone + Elotuzumab + Lenalidomide

Age Groups: senior | adult
Covered Countries DEU | AUT

No variant requirements are available.